Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$266.83 +4.3%	$260.15	$141.98 ▼ $304.39	$34.71B	0.3	832,934 shs	886,904 shs
BIIB Biogen	$131.32 -0.5%	$141.63	$128.51 ▼ $238.00	$19.22B	0.01	1.31 million shs	1.94 million shs
INCY Incyte	$62.33 +2.3%	$69.06	$50.35 ▼ $83.95	$12.06B	0.76	2.34 million shs	2.15 million shs
UTHR United Therapeutics	$312.26 +1.8%	$337.82	$225.62 ▼ $417.82	$14.02B	0.64	450,626 shs	461,017 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	-5.28%	-8.97%	+3.65%	+8.69%	+66.80%
BIIB Biogen	-3.52%	-5.12%	-6.03%	-13.66%	-38.54%
INCY Incyte	+0.59%	-1.88%	-17.13%	-11.81%	+7.54%
UTHR United Therapeutics	-0.45%	-3.11%	-4.09%	-13.03%	+34.44%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALNY Alnylam Pharmaceuticals	4.4071 of 5 stars	3.4	3.0	4.3	3.9	2.5	0.6
BIIB Biogen	4.8773 of 5 stars	4.2	5.0	3.7	2.9	2.5	1.9
INCY Incyte	4.6954 of 5 stars	3.1	3.0	3.1	2.9	3.3	3.1
UTHR United Therapeutics	4.9112 of 5 stars	3.3	4.0	4.6	3.0	3.3	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.77	Moderate Buy	$316.25	18.52% Upside
BIIB Biogen	2.43	Hold	$213.33	62.45% Upside
INCY Incyte	2.21	Hold	$74.88	20.13% Upside
UTHR United Therapeutics	2.67	Moderate Buy	$388.25	24.34% Upside

Current Analyst Ratings Breakdown

Latest INCY, ALNY, BIIB, and UTHR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/2/2025	ALNY Alnylam Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$500.00 ➝ $500.00
3/31/2025	ALNY Alnylam Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$338.00 ➝ $342.00
3/31/2025	ALNY Alnylam Pharmaceuticals	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$353.00
3/31/2025	ALNY Alnylam Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$300.00 ➝ $345.00
3/24/2025	ALNY Alnylam Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$280.00 ➝ $328.00
3/24/2025	INCY Incyte	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$69.00 ➝ $65.00
3/21/2025	ALNY Alnylam Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$338.00 ➝ $351.00
3/21/2025	ALNY Alnylam Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$385.00 ➝ $390.00
3/21/2025	ALNY Alnylam Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$310.00 ➝ $330.00
3/21/2025	ALNY Alnylam Pharmaceuticals	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
3/21/2025	ALNY Alnylam Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$300.00 ➝ $338.00

(Data available from 4/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$2.25B	15.44	N/A	N/A	$0.52 per share	513.13
BIIB Biogen	$9.68B	1.99	$21.56 per share	6.09	$114.71 per share	1.14
INCY Incyte	$4.24B	2.84	$0.48 per share	128.94	$17.82 per share	3.50
UTHR United Therapeutics	$2.88B	4.87	$18.78 per share	16.63	$127.35 per share	2.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	-$278.16M	-$2.17	N/A	299.81	N/A	-12.37%	N/A	-6.83%	5/1/2025 (Estimated)
BIIB Biogen	$1.63B	$11.19	11.74	7.95	1.51	16.87%	14.98%	8.76%	4/23/2025 (Estimated)
INCY Incyte	$32.62M	$0.27	230.86	9.53	0.41	0.77%	0.05%	0.04%	4/29/2025 (Estimated)
UTHR United Therapeutics	$984.80M	$24.60	13.71	11.36	0.97	40.31%	19.22%	16.15%	4/29/2025 (Estimated)

Latest INCY, ALNY, BIIB, and UTHR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/29/2025	N/A	INCY Incyte	$1.01	N/A	N/A	N/A	$996.17 million	N/A
4/23/2025	N/A	BIIB Biogen	$3.59	N/A	N/A	N/A	$2.25 billion	N/A
2/26/2025	Q4 24	UTHR United Therapeutics	$6.10	$6.19	+$0.09	$6.19	$734.74 million	$735.90 million
2/13/2025	Q4 2024	ALNY Alnylam Pharmaceuticals	-$0.62	-$0.65	-$0.03	-$0.65	$580.62 million	N/A
2/12/2025	Q4 2024	BIIB Biogen	$3.43	$3.44	+$0.01	$1.83	$2.42 billion	N/A
2/10/2025	Q4 2024	INCY Incyte	$1.57	$1.09	-$0.48	$1.02	$1.14 billion	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
INCY Incyte	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	15.27	2.78	2.71
BIIB Biogen	0.27	1.35	0.90
INCY Incyte	0.01	1.97	1.94
UTHR United Therapeutics	N/A	4.58	4.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BIIB Biogen	87.93%
INCY Incyte	96.97%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	1.50%
BIIB Biogen	0.16%
INCY Incyte	17.60%
UTHR United Therapeutics	11.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,000	130.09 million	127.52 million	Optionable
BIIB Biogen	8,720	146.38 million	146.14 million	Optionable
INCY Incyte	2,320	193.52 million	159.46 million	Optionable
UTHR United Therapeutics	980	44.91 million	39.33 million	Optionable

INCY, ALNY, BIIB, and UTHR Headlines

Recent News About These Companies

United Therapeutics Corp (UTHR) Recognized as a Top Employer by Fortune

April 2 at 1:41 PM | gurufocus.com

Is United Therapeutics Corporation (UTHR) The Most Profitable Biotech Stock To Buy Right Now?

April 2 at 10:30 AM | insidermonkey.com

United Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by Alliancebernstein L.P.

April 2 at 5:33 AM | marketbeat.com

Axiom Investors LLC DE Increases Position in United Therapeutics Co. (NASDAQ:UTHR)

April 2 at 5:25 AM | marketbeat.com

Wellington Management Group LLP Reduces Holdings in United Therapeutics Co. (NASDAQ:UTHR)

April 2 at 5:15 AM | marketbeat.com

United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Brandywine Global Investment Management LLC

April 2 at 5:07 AM | marketbeat.com

California Public Employees Retirement System Lowers Holdings in United Therapeutics Co. (NASDAQ:UTHR)

April 2 at 4:57 AM | marketbeat.com

Schroder Investment Management Group Lowers Stake in United Therapeutics Co. (NASDAQ:UTHR)

April 2 at 4:49 AM | marketbeat.com

Nomura Asset Management Co. Ltd. Has $8.69 Million Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

April 2 at 4:24 AM | marketbeat.com

Norges Bank Takes Position in United Therapeutics Co. (NASDAQ:UTHR)

April 2 at 4:22 AM | marketbeat.com

UniSuper Management Pty Ltd Sells 13,826 Shares of United Therapeutics Co. (NASDAQ:UTHR)

April 2 at 4:15 AM | marketbeat.com

Mitsubishi UFJ Asset Management Co. Ltd. Purchases 3,312 Shares of United Therapeutics Co. (NASDAQ:UTHR)

April 2 at 4:07 AM | marketbeat.com

Notable Monday Option Activity: UTHR, TEAM, UNH

April 2 at 3:41 AM | nasdaq.com

Arrowstreet Capital Limited Partnership Sells 99,154 Shares of United Therapeutics Co. (NASDAQ:UTHR)

April 1 at 5:09 AM | marketbeat.com

United Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by Pictet Asset Management Holding SA

April 1 at 4:32 AM | marketbeat.com

4,637 Shares in United Therapeutics Co. (NASDAQ:UTHR) Purchased by New Age Alpha Advisors LLC

April 1 at 4:31 AM | marketbeat.com

Korea Investment CORP Acquires 2,300 Shares of United Therapeutics Co. (NASDAQ:UTHR)

April 1 at 3:56 AM | marketbeat.com

United Therapeutics Co. (NASDAQ:UTHR) Short Interest Update

March 31 at 6:28 AM | marketbeat.com

Horizon Investment Services LLC Cuts Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

March 30 at 6:06 AM | marketbeat.com

Mitsubishi UFJ Trust & Banking Corp Has $16.13 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

March 30 at 4:41 AM | marketbeat.com

Is United Therapeutics (UTHR) The Most Expensive Stock Insiders Are Dumping In March?

March 30 at 2:36 AM | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INCY, ALNY, BIIB, and UTHR Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$266.83 +11.07 (+4.33%)

Closing price 04:00 PM Eastern

Extended Trading

$243.33 -23.50 (-8.81%)

As of 06:18 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Biogen NASDAQ:BIIB

$131.32 -0.71 (-0.54%)

Closing price 04:00 PM Eastern

Extended Trading

$129.08 -2.23 (-1.70%)

As of 07:18 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Incyte NASDAQ:INCY

$62.33 +1.42 (+2.33%)

Closing price 04:00 PM Eastern

Extended Trading

$59.00 -3.33 (-5.33%)

As of 06:55 PM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

United Therapeutics NASDAQ:UTHR

$312.26 +5.38 (+1.75%)

Closing price 04:00 PM Eastern

Extended Trading

$306.58 -5.68 (-1.82%)

As of 05:44 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time